Haematology Speciality Clinical Lead
Peter Hillmen is Consultant in Clinical Haematology at Leeds Teaching Hospitals NHS Trust and Honorary Professor of Haematology at the University of Leeds. He specialises in the management of lymphoproliferative disorders, aplastic anaemia and paroxysmal nocturnal haemoglobinuria (PNH).
Professor Hillmen was the Chief Investigator of a series of studies of eculizumab, a novel complement inhibitor in PNH, which ultimately led to its approval in 2007. He chairs the Global PNH Registry and the International PNH Interest Group (IPIG) and leads the Leeds National Commissioning Group Designated Centre for PNH, responsible for the care of patients with PNH from across most of the UK.
Professor Hillmen has chaired the chronic lymphocytic leukaemia (CLL) trials sub-group of the National Cancer Research Institute (NCRI) since 2002 and is a member of the Haematological Oncology Clinical Study Group of the NCRI.
He has published over 80 peer-reviewed papers in journals including The Lancet, New England Journal of Medicine, Blood and Journal of Clinical Oncology, has authored a number of book chapters and was Associate Editor of the Haematological Journal.